Home›Trial›NCT05363319
NCT05363319RECRUITING

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Study Summary

This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care. The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.

Conditions
Non-small Cell Lung Cancer
Interventions / Drugs
CemiplimabPlatinum-based chemotherapy
View on ClinicalTrials.gov ↗
Sponsor
REGN
Regeneron Pharmaceuticals
Antibody Therapeutics
D47/100
Study Details
Enrollment500 participants
Primary Completion—
Lead SponsorRegeneron Pharmaceuticals
Data Retrieved2026-04-11 02:55:54.866476+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 500 participants
Sponsor Catalyst Profile

Regeneron Pharmaceuticals (REGN) is the sponsoring company for this trial. BiotechSign currently grades this company D (47/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

REGN Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.